Evidence map›Paper›PMID 28628116›Full record

ArticleOncogene2017

Cadherin composition and multicellular aggregate invasion in organotypic models of epithelial ovarian cancer intraperitoneal metastasis.

Y Klymenko, O Kim, E Loughran, J Yang, R Lombard, M Alber, M S Stack

Open access · greenAbstract read
In one paragraph

Article in Oncogene, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed, 1 pooled it
3.1field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 1 synthesis or guideline pooled it, 81 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Tumor biomarkers for diagnosis, prognosis and targeted therapy.Signal transduction and targeted therapy · 2024
    Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Y KlymenkoDepartment of Biological Sciences, University of Notre Dame, Notre Dame, IN, USA.
O KimHarper Cancer Research Institute, University of Notre Dame, South Bend, IN, USA.
E LoughranHarper Cancer Research Institute, University of Notre Dame, South Bend, IN, USA.
J YangHarper Cancer Research Institute, University of Notre Dame, South Bend, IN, USA.
R LombardHarper Cancer Research Institute, University of Notre Dame, South Bend, IN, USA.
M AlberHarper Cancer Research Institute, University of Notre Dame, South Bend, IN, USA.
M S StackHarper Cancer Research Institute, University of Notre Dame, South Bend, IN, USA.
Cancer Research Institute · USUniversity of Notre Dame · US

Funding

Receptor Cross-Talk in Early Metastatic DisseminationR01CA109545 · NCI · UNIVERSITY OF NOTRE DAME · PI STACK, MARY SHARON · 2006 to 2022
$4.3M
REGULATION OF OVARIAN CARCINOMA PROTEINASESR01CA086984 · NCI · UNIVERSITY OF NOTRE DAME · PI STACK, MARY SHARON · 2000 to 2014
$3.8M
Multiscale modeling and empirical study of a mechanism limiting blood clot growthU01HL116330 · NHLBI · UNIVERSITY OF NOTRE DAME · PI ALBER, MARK · 2014 to 2018
$3.5M
NCI NIH HHS R01 CA086984NCI NIH HHS R01 CA109545NHLBI NIH HHS U01 HL116330
6 · The paper itself

Abstract

During epithelial ovarian cancer (EOC) progression, intraperitoneally disseminating tumor cells and multicellular aggregates (MCAs) present in ascites fluid adhere to the peritoneum and induce retraction of the peritoneal mesothelial monolayer prior to invasion of the collagen-rich submesothelial matrix and proliferation into macro-metastases. Clinical studies have shown heterogeneity among EOC metastatic units with respect to cadherin expression profiles and invasive behavior; however, the impact of distinct cadherin profiles on peritoneal anchoring of metastatic lesions remains poorly understood. In the current study, we demonstrate that metastasis-associated behaviors of ovarian cancer cells and MCAs are influenced by cellular cadherin composition. Our results show that mesenchymal N-cadherin-expressing (Ncad+) cells and MCAs invade much more efficiently than E-cadherin-expressing (Ecad+) cells. Ncad+ MCAs exhibit rapid lateral dispersal prior to penetration of three-dimensional collagen matrices. When seeded as individual cells, lateral migration and cell-cell junction formation precede matrix invasion. Neutralizing the Ncad extracellular domain with the monoclonal antibody GC-4 suppresses lateral dispersal and cell penetration of collagen gels. In contrast, use of a broad-spectrum matrix metalloproteinase (MMP) inhibitor (GM6001) to block endogenous membrane type 1 matrix metalloproteinase (MT1-MMP) activity does not fully inhibit cell invasion. Using intact tissue explants, Ncad+ MCAs were also shown to efficiently rupture peritoneal mesothelial cells, exposing the submesothelial collagen matrix. Acquisition of Ncad by Ecad+ cells increased mesothelial clearance activity but was not sufficient to induce matrix invasion. Furthermore, co-culture of Ncad+ with Ecad+ cells did not promote a 'leader-follower' mode of collective cell invasion, demonstrating that matrix remodeling and creation of invasive micro-tracks are not sufficient for cell penetration of collagen matrices in the absence of Ncad. Collectively, our data emphasize the role of Ncad in intraperitoneal seeding of EOC and provide the rationale for future studies targeting Ncad in preclinical models of EOC metastasis.

Indexed as

Disease Models, AnimalAnimalsCadherinsCarcinoma, Ovarian EpithelialCell AdhesionCell AggregationCell Line, TumorDipeptidesFemaleGene Expression Regulation, NeoplasticHumansMatrix Metalloproteinase 14Matrix Metalloproteinase InhibitorsMesodermMiceMice, Inbred C57BLCadherinsDipeptidesMatrix Metalloproteinase 14Matrix Metalloproteinase InhibitorsMMP14 protein, humanN-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide

Identifiers

PMID28628116
PMCPMC5648607
OpenAlexW2655582795

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.